Loratadin-Teva - Instructions For The Use Of Tablets, Price, Reviews, Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Loratadin-Teva

Loratadin-Teva: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Loratadine-Teva

ATX code: R06AX13

Active ingredient: loratadine (loratadine)

Manufacturer: Teva Pharmaceutical Plant, JSC (Hungary)

Description and photo update: 28.11.2018

Prices in pharmacies: from 90 rubles.

Buy

Loratadin-Teva is a blocker of H ₁ -histamine receptors, an antiallergic drug.

Release form and composition

Dosage form - tablets: oval, white, on one of the sides there is a dividing line and engraving "L" and "10" on both sides of the risks (7 pcs. In blisters, in a cardboard box 1 blister; 10 pcs. In blisters, in a cardboard box 1 or 3 blisters and instructions for the use of Loratadin-Teva).

Composition of 1 tablet:

• active substance: loratadine - 10 mg;
• auxiliary components: corn starch, magnesium stearate, pregelatinized starch, lactose monohydrate.

Pharmacological properties

Pharmacodynamics

The active ingredient of Loratadin-Teva - loratadine, is a selective blocker (antagonist) of peripheral H ₁ -histamine receptors. It has anti-allergic, antipruritic and anti-exudative properties. The mechanism of action of the drug is due to its ability to inhibit the degranulation of mast cells, to block secondary mediators of inflammation (prostaglandins and leukotrienes), to reduce the expression of cytokines and adhesion of molecules.

Loratadine has a weak affinity for muscarinic and alpha-adrenergic receptors. Does not bind to H ₂ -histamine receptors. Does not inhibit the seizure of norepinephrine. It has no significant effect on the heart rate and the function of the cardiovascular system.

The drug does not penetrate the blood-brain barrier. Does not affect the central nervous system. Virtually no sedative and anticholinergic effect. It has no incompatibilities with food, does not enhance the effects of alcohol. Not addictive.

Pharmacokinetics

Once in the gastrointestinal tract after oral administration, loratadine is well absorbed. It is characterized by the effect of the first passage through the liver. Due to biotransformation, a pharmacologically active metabolite, descarboethoxyloratadine, is formed.

With the normal functioning of the liver and kidneys, the maximum plasma concentration of loratadine is reached within 1.3 hours, for descarboethoxyloratadine - 2.5 hours.

Half-lives (T _½): loratadine - about 8 hours, descarboethoxyloratadine - about 28 hours.

Equilibrium plasma concentrations (C _max) of the active substance Loratadin-Teva and its main metabolite are reached by the 5th day of treatment.

The connection of loratadine with plasma proteins is 97-99%, descarboethoxyloratadine - 73-76%.

The volume of distribution (V _d) of loratadine is 119 l / kg.

The area under the concentration-time curve (AUC) of loratadine and its main metabolite depends on the dose of the drug taken. Simultaneous food intake has a slight effect on the pharmacokinetics of the drug, however, it slows down the time to reach C _max by 1 hour.

Loratadine and descarboethoxyloratadine pass into breast milk, creating concentrations similar to those in plasma.

Loratadine is metabolized in the liver with the participation of isoenzymes of the cytochrome P _{450 system} (to a greater extent - CYP3A4, to a lesser extent - CYP2D6).

After 10 days, about 80% of loratadine is excreted from the body in the form of metabolites by the kidneys and through the intestines (40% and 42%, respectively).

In elderly patients, the C _max and AUC of loratadine and descarboethoxyloratadine increase by 50%, and their T _½ is on average 18 hours.

In severe chronic renal failure (creatinine clearance <30 ml / min) C _max and AUC of loratadine and its active metabolite increase, but the mean T _½ does not change. In this case, the elimination of loratadine does not differ significantly from that in healthy volunteers. Hemodialysis does not affect the pharmacokinetics of the drug in patients with chronic renal failure.

In patients with alcoholic liver damage, the C _max and AUC of loratadine are doubled, and the same indicators for descarboethoxyloratadine do not differ significantly from those in patients with normal liver function. T _{½ of} loratadine and its metabolite averages 24 hours and 37 hours, respectively, these indicators increase in proportion to the severity of liver failure.

Indications for use

• seasonal and perennial allergic rhinitis;
• chronic idiopathic urticaria.

Contraindications

• glucose-galactose malabsorption, lactase deficiency, lactose intolerance;
• children under 3 years old;
• the period of pregnancy and breastfeeding;
• hypersensitivity to any component of the drug.

Loratadin-Teva tablets should be used with caution in patients with severe hepatic impairment and severe chronic renal impairment.

Loratadin-Teva, instructions for use: method and dosage

Loratadin-Teva tablets should be taken orally, before meals.

Recommended dosage:

• children 3–12 years old with body weight less than 30 kg - 5 mg once a day;
• children 3-12 years old weighing more than 30 kg - 10 mg 1 time per day;
• children over 12 years old (weighing more than 30 kg) and adults - 10 mg 1 time per day.

The duration of the therapeutic course is determined individually, depending on the duration of the manifestations of the symptoms of the disease. If after 3 days of regular intake of Loratadin-Teva there is no improvement in the condition, further administration of the drug is considered inappropriate.

Patients with severe chronic renal failure and severe hepatic insufficiency are prescribed 5 mg 1 time per day every day or 10 mg 1 time per day every other day.

Side effects

• from the nervous system: often (from ≥ 1% to <10%) - headache, nervousness; infrequently (from ≥ 0.1% to <1%) - insomnia, drowsiness; rarely (from ≥ 0.01% to <0.1%) - dizziness; in children - headache, sedation, increased nervous irritability;
• on the part of the cardiovascular system: rarely - a feeling of palpitations, tachycardia;
• from the digestive system: infrequently - increased appetite; rarely - dry mouth, nausea, liver dysfunction, gastritis;
• on the part of the skin and subcutaneous tissues: rarely - alopecia;
• allergic reactions: rarely - skin rashes, anaphylaxis;
• others: infrequently - feeling tired.

Overdose

An overdose of Loratadin-Tev is manifested by the following symptoms: drowsiness, headache, tachycardia. In children weighing less than 30 kg, after taking the drug at a dose of more than 10 mg, extrapyramidal disorders and a feeling of palpitations were recorded.

After taking an excessive dose, it is recommended to do a gastric lavage and take activated charcoal. Children use a 0.9% sodium chloride solution for washing, adults can use water. For the rapid elimination of loratadine from the gastrointestinal tract, enterosorbents and saline laxative solutions are prescribed. Hemodialysis and peritoneal dialysis are ineffective. Then symptomatic and supportive therapy is carried out.

special instructions

During the period of therapy, oral hygiene should be carefully observed, since loratadine can cause dry mouth, which is fraught with the development of caries.

Antihistamines can reduce or even hide positive skin reactions. In this regard, Loratadin-Teva should be canceled no later than 48 hours before the skin-allergic tests.

Influence on the ability to drive vehicles and complex mechanisms

Loratadin-Teva in some cases causes disorders of the central nervous system (dizziness, drowsiness), so patients are advised to be careful when performing potentially hazardous activities, including driving a car.

Application during pregnancy and lactation

The appointment of loratadine during pregnancy is contraindicated, since the data on the clinical use of the drug in pregnant women are insufficient to assess its safety.

Loratadine and its active metabolite are excreted in breast milk, therefore it is recommended to stop feeding for the period of therapy.

Pediatric use

Loratadin-Teva is not used to treat children under 3 years of age due to the lack of sufficient data on its safety and efficacy.

Children under 12 years of age weighing less than 30 kg Loratadin-Teva are prescribed in lower doses.

With impaired renal function

Drugs containing loratadine are used with caution in patients with chronic renal failure (if creatinine clearance is below 30 ml / min).

For violations of liver function

Loratadin-Teva is used with caution in patients with severe hepatic impairment.

Use in the elderly

Correction of the dosage regimen of Loratadin-Teva is not required for elderly patients.

Drug interactions

In the case of simultaneous use, loratadine reduces the maximum plasma concentration of erythromycin by 15%.

The maximum concentrations of loratadine and its active metabolite in the blood increase with the combined use of inhibitors of the isoenzyme CYP3A4 and / or CYP2D6 (for example, ketoconazole, erythromycin, cimetidine). However, clinically significant changes were not identified.

With the simultaneous use of alcohol, potentiation of the effects is not observed.

Analogs

Analogues of Loratadin-Teva are: Alerza, Alerpriv, Allegra, Allerfex, Glenzet, Desal, Desloratadin, Diazolin, Diphenhydramine, Dinox, Zinset, Zyrtec, Zodak, Kestin, Klallergin, Claridol, Ksizal, Levocetylaxine, Laurain Rapido, Suprastin, Tavegil, Feksadin, Fenistil, Fenkarol, Tsesera, Cetirizin, Cetirinax, Tsetrin, Erius, Elisey, etc.

Terms and conditions of storage

Store at temperatures up to 25 ° C out of the reach of children.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Available without a prescription.

Reviews about Loratadin-Teva

Patients leave mostly positive reviews about Loratadin-Teva, noting the high efficiency of the antiallergic agent, low cost, ease of use (1 time per day), no side effects (including drowsiness).

The price of Loratadin-Teva in pharmacies

Approximate prices for Loratadin-Teva (10 mg tablets): 7 pcs. in the package - 129–140 rubles., 10 pcs. in the package - 170-188 rubles., 30 pcs. in the package - 264-297 rubles.

Loratadin-Teva: prices in online pharmacies

Drug name Price Pharmacy

Loratadin-Teva 10 mg tablets 7 pcs. RUB 90 Buy

Loratadin-Teva 10mg tablets 10 pcs. 155 RUB Buy

Loratadin-Teva 10 mg tablets 10 pcs. 155 RUB Buy

Loratadin-Teva 10 mg tablets 30 pcs. 239 r Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!